Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/eojXCfbwocfFobcZrzQi

March 25, 2013
Are you part of a BD or licensing team and want to improve your skills in contracts, intellectual property, valuation and deal structuring? Register for BIO's Executive Training Courses, April 19-21, in Chicago.

The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at bio@smartbrief.com.

  Today's Top Story 
  • Report: 465 chronic-disease drugs are under development
    The U.S. biopharmaceutical industry is developing 465 new drugs that target the top 10 chronic diseases affecting individuals 65 and older, according to a Pharmaceutical Research and Manufacturers of America report. The lineup includes 40 for chronic obstructive pulmonary disease, 48 for heart failure, 82 for Alzheimer's, 92 for osteoarthritis and rheumatoid arthritis, and 142 for diabetes. Other treatments under development target osteoporosis, cataracts, depression and chronic kidney disease. PharmaTimes (U.K.) (3/22) LinkedInFacebookTwitterEmail this Story
  Health Care & Policy 
  • J&J threatens to put a wrinkle in Botox's dominance
    Johnson & Johnson expects to receive FDA approval next year for a wrinkle-reducing injection similar to Allergan's Botox. Allergan already faces competition from Valeant's Dysport and Merz's Xeomin, but it has an 85% market share. Reuters (3/22) LinkedInFacebookTwitterEmail this Story
  • Alimera again submits DME drug Iluvien for U.S. approval
    Alimera Sciences plans to resubmit Iluvien, a drug candidate for chronic diabetic macular edema, for FDA approval by the end of this month. Alimera licensed the drug from pSivida. The application will highlight the drug's safety profile and will focus on chronic DME patients who don't respond satisfactorily to existing treatments. The drug has been approved in the U.K., Germany, France and several other European countries. In 2011, the FDA requested additional trials. ProactiveInvestors.co.au (Australia) (3/25), Australian Life Scientist (3/25) LinkedInFacebookTwitterEmail this Story
  Company & Financial News 
  Food & Agriculture 
  Hot Topics 

Top five news stories selected by BIO SmartBrief readers in the past week.

  • Results based on number of times each story was clicked by readers.
  Industrial & Environmental 
  • Report: 10 cellulosic fuel plants could go online through 2014
    At least 10 commercial-scale cellulosic biofuel plants are expected to go online through next year, according to a report from a pair of researchers at the Bioeconomy Institute at Iowa State University. The projects include a Sundrop Fuels facility in Alexandria, La., and a KiOR project in Natchez, Miss. BiofuelsDigest.com (3/22) LinkedInFacebookTwitterEmail this Story
  News from BIO 
  • Ship with FedEx
    FedEx is now offering member companies discounts of up to 35% off select FedEx services, both U.S. and international services. The BIO program with FedEx is one of the many cost-savings programs offered by BIO through its Business Solutions program. There is no charge for BIO member companies to participate in any of the BIO Business Solutions programs -- it is a benefit of membership. Learn more about the BIO and FedEx program. LinkedInFacebookTwitterEmail this Story
Learn more about BIO ->Conferences  |  Join BIO  |  Media  |  Issues  |  Industry

  SmartQuote 
A thing is mighty big when time and distance cannot shrink it."
--Zora Neale Hurston,
American author


LinkedInFacebookTwitterEmail this Story

 
 
Subscriber Tools
     
Print friendly format | Web version | Search past news | Archive | Privacy policy

Advertise
Account Director:  Meryl Harold (202) 407-7828
 
Read more at SmartBrief.com
A powerful website for SmartBrief readers including:
 
 
 Recent BIO SmartBrief Issues:   Lead Editor:  Tom Parks
     
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
 
 
© 1999-2013 SmartBrief, Inc.® Legal Information